Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

We were able to analyze and compare the distribution of selected SNPs analyzed in the present study with regard to various bone parameters such as calcium and alkaline phosphatase levels, vitamin D, TSH levels (Table 4), number of painful and swollen joints and VAS score (Table 5).Distribution of the RANK and RANKL genotypes with regard to biochemical parameters level presented as mean (± SD)GeneGenotypeCalcium [mg/dl]Alkaline phosphatase [U/l]Vitamin D3 [ng/ml]TSH [ulU/ml]RANK rs8086340CC9.59 (± 0.42)104.7 (± 65.9)a23.9 (± 9.65)1.52 (± 1.38)CG9.57 (± 0.42)72.3 (± 21.0)20.3 (± 8.07)1.27 (± 0.72)GG9.58 (± 0.40)81.4 (± 32.5)22.7 (± 11.1)1.36 (± 0.92)RANK rs1805034CC9.56 (± 0.26)92.3 (± 32.5)b20.2 (± 6.15)1.32 (± 0.72)CT9.67 (± 0.39)78.2 (± 42.3)20.1 (± 8.46)1.43 (± 0.73)TT9.51 (± 0.48)77.3 (± 29.7)24.8 (± 12.3)1.28 (± 1.15)cRANKL rs7325635GG9.57 (± 0.40)80.9 (± 42.3)20.2 (± 9.39)1.31 (± 0.93)GA9.51 (± 0.38)76.8 (± 27.0)21.4 (± 8.49)1.40 (± 0.69)AA9.76 (± 0.43)89.7 (± 38.4)27.4 (± 13.4)1.32 (± 1.25)RANKL rs7988338GG9.61 (± 0.43)80.2 (± 29.7)22.4 (± 10.2)1.39 (± 0.99)GA9.49 (± 0.35)83.0 (± 52.0)22.0 (± 9.93)1.19 (± 0.69)AA9.80 (± 0.26)82.0 (± 13.1)15.5 (± 0.00)1.55 (± 0.64)ap = 0.057bp = 0.035cp = 0.052Distribution of the RANK and RANKL genotypes with respect to the number of painful or swollen joints and visual analogue scale (VAS) for pain score presented as mean (± SD) (at baseline and at the 12th week of the therapy)GeneNumber of painful joints at baselineNumber of painful joints at 12th weekNumber of swollen joints at baselineNumber of swollen joints at 12th weekVAS [mm] at baselineVAS [mm] at 12th weekRANK rs8086340CC15.9 (± 6.30)9.64 (± 5.61)11.4 (± 6.26)6.00 (± 5.49)76.7 (± 11.6)44.9 (± 17.4)CG16.3 (± 5.14)9.29 (± 6.38)12.6 (± 5.82)7.00 (± 6.94)76.7 (± 12.3)48.9 (± 17.0)GG18.2 (± 5.60)8.87 (± 5.46)12.8 (± 5.80)5.50 (± 4.71)75.2 (± 9.49)46.9 (± 19.4)RANK rs1805034CC18.1 (± 5.69)8.86 (± 5.72)12.4 (± 5.93)5.24 (± 4.57)75.4 (± 12.1)49.2 (± 14.7)CT16.3 (± 5.06)8.71 (± 6.25)11.8 (± 5.74)6.40 (± 6.17)74.4 (± 10.7)44.6 (± 18.6)TT17.6 (± 5.97)9.83 (± 5.46)13.4 (± 5.87)6.57 (± 6.18)78.1 (± 10.1)49.6 (± 19.5)RANKL rs7325635GG17.9 (± 5.09)10.1 (± 5.79)13.1 (± 6.34)7.82 (± 6.41)a76.1 (± 9.47)47.2 (± 18.9)GA17.1 (± 6.10)8.51 (± 6.00)12.4 (± 5.10)4.49 (± 4.75)75.7 (± 13.2)44.3 (± 18.5)AA16.0 (± 5.34)8.41 (± 5.49)11.6 (± 6.18)6.35 (± 5.74)76.2 (± 8.67)54.3 (± 14.1)RANKL rs7988338GG16.7 (± 5.60)9.03 (± 5.60)11.7 (± 5.59)b5.90 (± 5.05)75.0 (± 11.5)49.4 (± 17.1)GA18.4 (± 5.44)9.17 (± 6.62)14.4 (± 6.03)6.48 (± 7.51)79.0 (± 8.19)43.2 (± 19.2)AA20.0 (± 2.83)12.0 (± 2.83)17.5 (± 6.36)11.0 (± 4.24)74.0 (± 8.48)35.5 (3 ± 4.6)ap = 0.035bp = 0.045

Source: Relationship between Patients’ Genotypes and Bone Parameters or Thyroid Dysfunction. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were classified according to the 2010 American College of Rheumatology criteria, as well as by the presence of active disease represented by the Disease Activity Score in 28 joints ([DAS28] ≥ 5.1) prior to initiating biologic agent therapy.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment

Study design awaiting verification · Archivum Immunologiae et Therapiae Experimentalis · 2020

Original publication title

Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment

Joanna Wielińska; Katarzyna Kolossa; Jerzy Świerkot; Marta Dratwa; Milena Iwaszko; Bartosz Bugaj; Barbara Wysoczańska; Monika Chaszczewska-Markowska; Sławomir Jeka; Katarzyna Bogunia-Kubik

© The Author(s) 2020

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Inconsistency of the results regarding the genetic variability within genes coding for receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) in rheumatoid arthritis (RA) prompted us to study the RANK and RANKL polymorphisms as potential biomarkers associated with disease predisposition and response to anti-TNF treatment in a group of Polish patients with RA. This study enrolled 318 RA patients and 163 controls. RANK (rs8086340, C > G; rs1805034, C > T) and RANKL (rs7325635, G > A; rs7988338 G > A) alleles were determined by real-time PCR with melting curve analysis and related with clinical parameters.

In addition, RANKL serum levels were measured by ELISA. The RANK rs8086340-G allele was overrepresented among patients as compared to controls (OD = 1.777, p = 0.038). C-reactive protein (CRP) levels were significantly (p < 0.05) associated with RANK rs8086340 polymorphism and were higher in the CC-homozygotes at the baseline while lower in the GG-carriers at the 12th week of the treatment. At the latter time point RANKL rs7325635-GG-positive patients also showed significantly lower CRP concentrations.

Higher alkaline phosphatase levels before induction of anti-TNF therapy were observed in RANK rs8086340 and RANK rs1805034 CC homozygotes (p = 0.057 and p = 0.035, respectively). The GG homozygosity of both RANKL single nucleotide polymorphisms was significantly associated with the number of swollen joints (rs7988338 and rs7325635, before and at the 12th week of therapy, respectively, p < 0.05 in both cases). These results imply that polymorphisms within the RANK and RANKL genes affect RA susceptibility and anti-TNF treatment outcome.

Authors’ abstract

Inconsistency of the results regarding the genetic variability within genes coding for receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) in rheumatoid arthritis (RA) prompted us to study the RANK and RANKL polymorphisms as potential biomarkers associated with disease predisposition and response to anti-TNF treatment in a group of Polish patients with RA. This study enrolled 318 RA patients and 163 controls. RANK (rs8086340, C > G; rs1805034, C > T) and RANKL (rs7325635, G > A; rs7988338 G > A) alleles were determined by real-time PCR with melting curve analysis and related with clinical parameters.

In addition, RANKL serum levels were measured by ELISA. The RANK rs8086340-G allele was overrepresented among patients as compared to controls (OD = 1.777, p = 0.038). C-reactive protein (CRP) levels were significantly (p < 0.05) associated with RANK rs8086340 polymorphism and were higher in the CC-homozygotes at the baseline while lower in the GG-carriers at the 12th week of the treatment. At the latter time point RANKL rs7325635-GG-positive patients also showed significantly lower CRP concentrations.

Higher alkaline phosphatase levels before induction of anti-TNF therapy were observed in RANK rs8086340 and RANK rs1805034 CC homozygotes (p = 0.057 and p = 0.035, respectively). The GG homozygosity of both RANKL single nucleotide polymorphisms was significantly associated with the number of swollen joints (rs7988338 and rs7325635, before and at the 12th week of therapy, respectively, p < 0.05 in both cases). These results imply that polymorphisms within the RANK and RANKL genes affect RA susceptibility and anti-TNF treatment outcome.

Publication and source details

Original title: Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment

Joanna Wielińska; Katarzyna Kolossa; Jerzy Świerkot; Marta Dratwa; Milena Iwaszko; Bartosz Bugaj; Barbara Wysoczańska; Monika Chaszczewska-Markowska; Sławomir Jeka; Katarzyna Bogunia-Kubik

Archivum Immunologiae et Therapiae Experimentalis · 2020

© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100004281Narodowe Centrum Nauki2016/21/B/NZ5/01901Bogunia-Kubik Katarzyna

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T14:41:07.890862+00:00

DOI: 10.1007/s00005-020-00590-6 · PMC7438366